The stock of Baxter International Inc. (NYSE:BAX) increased by increased by $0.73 on Friday to finish at $82.19, up 0.90 percent. The last five days have seen an average of 1,863,580 shares of common stock traded. 12 times new highs were reached in the current year, with a gain of $1.95. The average number of shares traded over the last 20 days was 2,314,890, while the average volume over the last 50 days totaled 3,125,998.
BAX stock appreciated 1.73% since last month. On 10/18/21, the company’s shares reached a one-month low of $77.94. The stock touched a high of $88.32 on 04/23/21, after rallying from a low of $73.12 in 52 weeks. The price of BAX stock has risen by 2.43% or $1.95 this year, reaching a new high 12 times. Still, the stock price is down -6.94% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 84 days since Baxter International Inc. (BAX) last reported insider trading activity on Aug 02. On Aug 02, SVP and General Counsel Martin Sean sold 19,800 shares at $77.26 each. This transaction resulted in the insider making $1,529,748. On Apr 12, Frye Andrew sold 10,999 shares at a price of US$84.79. After the transaction, the insider now owns 9,041 shares. Director STROUCKEN ALBERT P L had earlier sold 4,990 shares on Apr 05 for $84.56 a share. The transaction was completed for $421,954.
Baxter International Inc. (BAX) has a trailing price-to-earnings (P/E) ratio of 37.68. This level actually compares favorably with the industry at large, as the PE for the Medical Instruments & Supplies industry stands at about 42.68. Further, its PE also compares unfavorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of Baxter International Inc. has varied between 56.02 and 4.891 in the last five years. Beta for the stock is 0.61. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.34, the price-to-book (PB) ratio of 4.87, and the price-to-cash flow ratio of 47.63.
Baxter International Inc.’s dividend is $1.12 per share per year. With a dividend yield of 1.36%, BAX has a payout ratio of 45.90%. On Oct. 1, the company paid $0.28 per share in dividends, remained unchanged from $0.28 last year. A $0.0350 dividend increase was reported on Monday May 3 2021, making it the 5 consecutive year the dividend has increased. Over the last three years, dividends have increased by 56.56%.
For the three months ended June 29, Baxter International Inc.’s quick ratio was 1.80, while its current ratio was 2.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.67, and the total debt to equity ratio is 0.73. As far as profitability goes, gross margin for the trailing twelve months is 39.60% percent. Baxter International Inc.’s operating margin stood at 12.60% for the same period. Based on annual data, it had gross profit of $4.59 billion and revenue of $11.67 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BAX’s return on assets (ROA) during the last 12 months has been 5.70%. There was a 8.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 13.10%. ROE has averaged 3.96 in the past year for the broader industry.
According to Baxter International Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Baxter International Inc.’s quarterly earnings would be $0.8, but it ended up being $0.75, beating the consensus by 6.70%. EBITDA was $646.0 million for the quarter. At the end of Baxter International Inc.’s most recent quarter ended June 29, its liabilities totaled 11.15 billion, while its total debt was $6.64 billion. Equity owned by shareholders amounts to $499.91 million.
Here’s a quick look at Baxter International Inc.’s (BAX) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 64.39%, suggesting the stock is Neutral, with a 18.10% historical volatility rate.
The stochastic %K and %D were 86.55% and 64.37% respectively, while the average true range (ATR) was 1.28. Based on the 14-day stochastic reading of 98.95%, the RSI (14) reading is 59.78%. On the 9-day MACD Oscillator, the stock is at 1.65, and the 14-day reading is at 1.54.
In its most recent analyst report, Cowen raised its rating on Baxter International Inc. (NYSE: BAX) to an Outperform. Prior to this, analysts firm rated the stock as a Market perform. Analysts have assigned Baxter International Inc. (BAX) an Overweight rating. BAX is a stock that is recommended for selling by 0 brokerage firms, while 6 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 9 others recommend it as a buy.
What is BAX’s price target for the next 12 months?
The current consensus forecast for the stock is between $82.00 and $105.00, with a median target price of $95.50. In analyzing these forecasts, the average price target given by analysts for Baxter International Inc. (BAX) is $94.57.